Zimmer Biomet, a major player in the medical technology field, recently entered into an agreement with NeuroOne Medical Technologies to obtain exclusive distribution rights for OneRF ablation system, designed specifically to target the brain tissues responsible for seizure activity. This advance marks a significant turning point in the treatment of epilepsy, offering new perspectives for patients seeking innovative solutions. By securing this technology, Zimmer strengthens its commitment to the neurological sector and paves the way for more precise and efficient surgical procedures.
Summary of Zimmer Acquisition of NeuroOne Brain Ablation System
Zimmer Biomet expanded its partnership with NeuroOne Medical Technologies by obtaining exclusive rights for the OneRF Ablation System, specifically for its use in the brain. As part of this agreement, NeuroOne will receive 3 million dollars in advance, as well as a potential million dollars in sales milestones. The device, recently approved by the FDA, is designed to identify and ablate brain tissue responsible for seizure activity. The commercial launch of the product began in March. This transaction represents an opportunity for NeuroOne to inject funds and support from an organization capable of boosting sales of this promising technology.
Zimmer Biomet recently expanded its collaboration with NeuroOne Medical Technologies to obtain exclusive rights related to the ablation system OneRF, designed to treat brain pathologies. This acquisition marks a significant advance in the medical field, offering new perspectives for the treatment of epileptic disorders. The Food and Drug Administration (FDA) has approved the use of this system, paving the way for its commercial deployment.
Details of the agreement
Under the agreement, NeuroOne will receive an initial payment of $3 million, in addition to a potential payment of up to $1 million depending on sales. The OneRF system is particularly innovative because it makes it possible to identify and ablate brain tissues that generate epileptic seizures. Thanks to this technology, NeuroOne expects to achieve significant sales, supported by Zimmer’s expertise and resources.
Market impact and innovation
This alliance is likely to improve the visibility and the distribution of NeuroOne devices in a growing market. With increased marketing support, both companies hope to increase revenue. NeuroOne had already achieved approximately $826,000 in product revenue, and the introduction of OneRF is expected to fuel this growth in the coming months. Health professionals, armed with these new tools, will have the capacity to improve the fate of patients suffering from epilepsy.
